JPM 2021: Boston Scientific, Abbott, Dexcom, Insulet, Silk Road Medical
Executive Summary
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.
You may also be interested in...
Analysts Are Bullish On Insulet’s Omnipod 5 For Managing Type 1 Diabetes
A trial of Insulet’s Omnipod 5 trial in children and adults showed improvements in time and range and hemoglobin A1c after three months of use compared to standard therapy.
Boston Scientific Is Counting On COVID-19 Vaccine To Rebound In 2021
The company expects revenues across its businesses to rapidly return to their pre-pandemic growth rates in the second half of 2021.
Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.